Sanofi (SNY) EPS (Basic) Growth (3y) (2012 - 2026)
Sanofi (SNY) EPS (Basic) Growth (3y) (2012 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EPS (Basic) Growth (3y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Johnson & Johnson | 653.59 Bn | 632.83 Bn | 17.26 Bn | 5.11% |
| 2 | AbbVie | 470.48 Bn | 463.91 Bn | 12.70 Bn | 21.23% |
| 3 | Merck | 375.12 Bn | 367.98 Bn | 12.21 Bn | 38.72% |
| 4 | Novartis Ag | 302.96 Bn | 295.27 Bn | 11.24 Bn | -59.02% |
| 5 | Astrazeneca | 257.26 Bn | 252.36 Bn | 12.86 Bn | 11.28% |
| 6 | Amgen | 237.14 Bn | 223.15 Bn | 7.24 Bn | 19.50% |
| 7 | Gilead Sciences | 182.99 Bn | 179.82 Bn | 6.22 Bn | -129.90% |
| 8 | Pfizer | 160.23 Bn | 148.53 Bn | 10.94 Bn | -28.08% |
| 9 | Gsk | 106.11 Bn | 101.94 Bn | 8.24 Bn | -34.06% |
| 10 | Sanofi | 55.21 Bn | 47.83 Bn | 10.79 Bn | -35.71% |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -92.01% |
| Mar 31, 2026 | -2.90% |
| Dec 31, 2025 | -51.42% |
| Sep 30, 2025 | 70.21% |
| Jun 30, 2025 | 53.66% |
| Mar 31, 2025 | -4.02% |
| Dec 31, 2024 | -54.87% |
| Sep 30, 2024 | 4.35% |
| Jun 30, 2024 | -5.97% |
| Mar 31, 2024 | -13.29% |
| Dec 31, 2023 | -26.92% |
| Sep 30, 2023 | 6.50% |
| Jun 30, 2023 | -42.82% |
| Mar 31, 2023 | 4.90% |
| Dec 31, 2022 | 686.25% |
| Sep 30, 2022 | 2.09% |
| Jun 30, 2022 | 145.50% |
| Mar 31, 2022 | 20.28% |
| Dec 31, 2021 | 7.71% |
| Sep 30, 2021 | 0.79% |